Blog Details

GLP-1 Receptor Agonists Beyond Diabetes: Why Cardiologists and Nephrologists Are Paying Attention

19-July-2025  |  Fitness & Exercise

For many years, GLP-1 receptor agonists have been largely considered anti-diabetic drugs. But, the perception has been changing over the past few years, thanks to cardiovascular and renal outcome trials. Emerging data indicate that drugs like Semaglutide provide clinically relevant additional benefits beyond glycemic control, especially in individuals with obesity, existing cardiovascular diseases, and chronic kidney disease. 

HbA1c reduction and weight loss are no longer the only criteria for discussion. Data now increasingly look at hard outcomes such as major adverse cardiovascular events (MACE), renal decline, hospitalization, and mortality. 

The SELECT Trial and Cardiovascular Outcomes of Insights. 

The SELECT trial, published recently in The New England Journal of Medicine, is one of the most talked about studies in this area. 

The trial tested overweight or obese adults with existing cardiovascular disease, who did not have diabetes. The published data showed that semaglutide, administered once a week, significantly reduced major cardiovascular events, such as cardiovascular death, nonfatal myocardial infarction and stroke. 

The relevance of the findings was that it seemed as though the cardiovascular benefit, apart from glucose lowering, was present. This has stirred many issues about inflammatory modulation, endothelial function and cardiometabolic risk reduction with GLP1 receptor activation. 

Later, subgroup analyses published in The Lancet indicated favourable results in patients with obesity and with concomitant heart failure. 

Renal Protection: Emerging Data from the FLOW Trial

Another major development came from the FLOW trial, which evaluated semaglutide in patients with type 2 diabetes and chronic kidney disease.

Published findings demonstrated reduced risk of clinically significant kidney outcomes, slower eGFR decline, and lower cardiovascular mortality compared with placebo.

Several nephrology discussions following the trial have pointed toward a possible shift in how GLP-1 receptor agonists may eventually be integrated into CKD management algorithms, especially in diabetic CKD populations already receiving SGLT2 inhibitors and RAAS blockade.

While SGLT2 inhibitors continue to remain foundational in nephroprotection, the FLOW data have added momentum to the concept of combination cardiometabolic therapy.

Clinical Relevance Beyond Weight Reduction

One key finding from recent studies and analyses is that the cardiovascular effects of semaglutide are not necessarily attributed solely to weight loss. 

Further SELECT exploratory analyses have indicated that reductions in inflammatory burden and vascular health and metabolic regulation are independent pathways to cardiovascular risk reduction. 

The difference is clinically meaningful because it may shift the thinking of GLP-1 receptor agonists from obesity therapy to using them as cardiovascular risk-modifiers. 

Current Questions Still Under Discussion

Despite encouraging data, several areas still require long-term clarification:

• Durability of benefit after discontinuation
• Cost-effectiveness in broader populations
• Real-world adherence outside clinical trials
• Safety in frail or elderly CKD populations
• Role in non-diabetic cardiovascular disease management

Ongoing real-world evidence studies and post-marketing analyses are expected to further define patient selection and long-term outcomes over the next few years.

Conclusion

Recent cardiovascular and renal outcome trials have significantly expanded the conversation around GLP-1 receptor agonists. What initially entered practice as glucose-lowering therapy is now being evaluated as part of a broader cardiometabolic disease-modifying strategy.

For clinicians managing obesity, cardiovascular disease, diabetes, or CKD, the emerging evidence around semaglutide is becoming increasingly difficult to ignore — not because of weight loss trends, but because of outcome-driven data now appearing across multiple specialties.

References & Source Material

• The New England Journal of Medicine — SELECT Trial: Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes
• American College of Cardiology — SELECT Trial Summary & Clinical Interpretation
• The Lancet — Heart Failure Analysis from SELECT
• The New England Journal of Medicine — FLOW Trial: Effects of Semaglutide on Chronic Kidney Disease
• American Society of Nephrology — FLOW CKD Severity Analysis